I vaguely remember reading a GS analyst report on it and they considered it worth 50 a share, but were not that hopeful on it being a sucess. It was a report on the R&D pipeline and so they "risk adjusted" all the potential drugs based on chances of sucess multipled by market potential. I think other media reporting on the drug have suggested it could earn $1b a year in revenue at high profit margin, perhaps others can confirm or clarify? I'll take a stab and guess that if it's successful the stock could re-rate 10%.
Garadacimab and csl112, page-5
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$283.39 |
Change
-2.340(0.82%) |
Mkt cap ! $137.2B | |||
| Open | High | Low | Value | Volume |
| $286.25 | $287.25 | $281.40 | $132.1M | 466.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1086 | $283.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $283.39 | 3 | 1 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |